A b s t r a c t
Measurement of lactate levels is important in the assessment of severely ill adults and children. Recently, more point-ofcare platforms and blood gas analyzers have added lactate measurement to allow testing in a stat laboratory or point-of-care application. The National Academy of Clinical Biochemistry draft guidelines on evidence-based practice for point-of-care testing conclude that more rapid turnaround time of lactate results in critically ill patients leads to improved clinical outcomes. 1 Thus, use of point-of-care lactate measurement methods seems to be clinically justified. However, no study has compared lactate values obtained from multiple central laboratory (plasmabased assays) and point-of-care (whole blood) platforms to determine whether clinically relevant discrepancies might occur if testing is performed on both plasma (central laboratory) and whole blood (point-of-care or blood gas analyzer) platforms.
We compared 2 plasma-based lactate assays with 3 whole blood applications. The plasma-based assays were Lactate Gen.2 performed on a Roche Cobas Integra 400 analyzer (Roche Diagnostics, Indianapolis, IN) and the Vitros LAC slide assay performed on a Vitros 250 analyzer (Ortho Clinical Diagnostics, Rochester, NY). Whole blood applications included the i-STAT (i-STAT, East Windsor, NJ), Radiometer ABL 725 blood gas analyzer (Radiometer Medical A/S, Bronshoj, Denmark), and the newly developed Lactate Plus (Nova Biomedical, Waltham, MA). All tests are approved by the Food and Drug Administration for lactate determination except the Nova Lactate Plus Meter, which is currently for investigational use only.
Materials and Methods
Deidentified lithium heparin whole blood specimens obtained from patients in the emergency department and intensive care units (n = 90) were analyzed on the Radiometer ABL 725, the i-STAT CG4+, and the Nova Lactate Plus within 1 to 2 minutes of each other. Samples were transported to the laboratory at ambient temperature, and all whole blood analysis was completed within 1 hour of draw time. Within 5 minutes of whole blood analysis, the specimens were centrifuged and plasma separated and kept on ice until testing on the Roche Integra and the Vitros 250 analyzers could be completed (within 1 hour of plasma separation). Linearity and precision of each device or assay was also performed using material provided by the individual manufacturers. The study design was approved by the Mayo Clinic Institutional Review Board.
There is currently no reference standard for lactate measurement. The Vitros LAC slide assay, currently the primary method in our laboratory, was originally validated by the manufacturer against an ion exclusion chromatography method. It showed excellent agreement with this nonenzymatic method (slope, 0.99; intercept, 0.18 mg/dL [0.02 mmol/L]; correlation coefficient, 1.00; samples ranged from 9.0-122.5 mg/dL [1.0-13.6 mmol/L]). 2 Vitros interassay precision in our laboratory during a 1-month period yields coefficients of variation (CVs) of less than 10% across the range of lactate values typically encountered. The manufacturer of the Lactate Gen.2 assay validated its performance on the Integra by comparing results with the same reagent run on a Hitachi 917 analyzer and by comparing with results of a previous generation lactate assay run on the Integra. 3 Because there is no single reference method or standard for lactate, evaluation of the point-of-care lactate methods was performed by comparing results with the Vitros assay alone and with the averaged result of the Vitros and Integra methods.
To assess the clinical importance of differences in lactate values observed between methods, the percentage of concordance (compared with the Vitros) within clinically relevant ranges was calculated. Results were classified as low risk (lactate result, ≤19. 
Results
Linearity evaluation for each method using material provided by the individual vendors demonstrated 95% to 105% recovery of the expected values between lactate levels of 9.0 and 126.1 mg/dL (1-14 mmol/L) for all methods tested (the Nova Lactate Plus did not have linearity material available).
Precision experiments on the Radiometer ABL 725, i-STAT, and Integra methods demonstrated that the CV was 3% or less when control material was run 20 times during 7 to 10 days covering ranges of lactate levels of 9.0 to 81.1 mg/dL (1-9 mmol/L). For the Nova meter, precision was assessed by running control samples at 2 levels 20 times during 10 days: CVs were 15.8% at low (15.3 mg/dL [1.7 mmol/L) and 4.3% at high (63.1 mg/dL [7. 0 mmol/L]) levels.
Method correlation by least squares regression (using the Vitros as reference standard) yielded slopes of 0.95 for the Integra 400 Plus, 0.87 for the Radiometer ABL and i-STAT, and 1.06 for the Nova, with r 2 of 0.99 or more in each case, indicating strong correlation between the methods. Intercepts were between lactate levels of 0.9 and 1.8 mg/dL (0.1-0.2 mmol/L) for all methods. Because the Vitros and Integra methods correlated extremely well, the averaged result from the 2 plasma methods was also used as a reference method to compare the performance of the 3 whole blood assays. When this was done, the slopes and intercepts of the least squares regression fit for the Radiometer (slope, 0.88; intercept, 0.06), i-STAT (slope, 0.89; intercept, 0.09), and Nova (slope, 1.08; intercept, 0.14) methods changed little. Bland-Altmann plots of the 4 assays (vs the Vitros LAC) are shown in ❚Figure 1❚ and ❚Figure 2❚. The Roche Integra 400 Lactate Gen.2 assay correlated most closely with the Vitros method. The Radiometer and i-STAT assays exhibited negative bias (relative to the Vitros) at high lactate values, whereas the Nova Lactate Plus method exhibited a positive bias relative to the Vitros (Figures 1 and 2) .
Sample stability was addressed in 2 separate experiments using whole blood or plasma. Ten whole blood lithium heparin specimens were kept on ice for up to 30 minutes. The mean lactate concentration for the 10 specimens at time 0 was 45.9 mg/dL (5.1 mmol/L; range, 11.7-144.1 mg/dL [1.3-16.0 mmol/L]), and the lactate concentration changed by 1.8 mg/dL (0.2 mmol/L) or less in each specimen during the 30 minutes on ice. In a similar experiment, 10 whole blood specimens were separated into lithium heparin plasma and kept on ice up to 2 hours. The mean lactate concentration at time 0 was 39. 
Discussion
Point-of-care or stat laboratory (ie, whole blood) lactate testing is increasingly common and increasingly justified based on medical benefits. 1 However, few studies have been published correlating plasma-based with whole blood measurements of lactate levels. One previous study found a strong correlation between the lactate level measured on a Radiometer ABL 700 series instrument and a Vitros but did not include other point-of-care methods or discuss the clinical relevance of any differences. 7 Another recent study found that lactate levels measured on 2 different blood gas analyzers correlated very well, but this study did not compare values with those from a plasma-based method. 8 In this study, we compared 5 different methods for lactate determination-3 whole blood applications and 2 plasma-based laboratory methods. The Integra 400 lactate assay correlates very closely with the Vitros method, such that the 2 methods could be used interchangeably with differences in clinical interpretation of results being uncommon.
For the Radiometer and i-STAT methods 2 of 31 samples that would have been classified as high risk by central laboratory (plasma) analysis would have been classified as intermediate risk by point-of-care (whole blood) measurement. This could be particularly problematic if the first measurement were performed on a point-of-care platform and a follow-up 
